[EN] FUSED HETEROCYCLES AS 5-HT2A RECEPTOR AGONISTS [FR] HÉTÉROCYCLES FUSIONNÉS UTILISÉS EN TANT QU'AGONISTES DU RÉCEPTEUR 5-HT2A
摘要:
The disclosure provides compounds, e.g., compounds of Formula I, and their use in treating medical diseases or disorders, such as neurological disorders. Pharmaceutical compositions and methods of making various azaindole and benzisoxazole compounds are provided. The compounds are contemplated to be modulators of the 5-hydroxytryptamine 2A (5-HT2A) receptor.
BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN
申请人:Global Blood Therapeutics, Inc.
公开号:US20150259296A1
公开(公告)日:2015-09-17
Provide herein are compounds and pharmaceutical compositions suitable as modulators of hemoglobin, methods and intermediates for their preparation, and methods for their use in treating disorders mediated by hemoglobin and disorders that would benefit from tissue and/or cellular oxygenation.
COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN
申请人:Global Blood Therapeutics, Inc.
公开号:US20170174654A1
公开(公告)日:2017-06-22
Provide herein are compounds and pharmaceutical compositions suitable as modulators of hemoglobin, methods and intermediates for their preparation, and methods for their use in treating disorders mediated by hemoglobin and disorders that would benefit from tissue and/or cellular oxygenation.
Compounds and uses thereof for the modulation of hemoglobin
申请人:Global Blood Therapeutics, Inc.
公开号:US09422279B2
公开(公告)日:2016-08-23
Provide herein are compounds and pharmaceutical compositions suitable as modulators of hemoglobin, methods and intermediates for their preparation, and methods for their use in treating disorders mediated by hemoglobin and disorders that would benefit from tissue and/or cellular oxygenation.